XL413·HCl
Cdc7 inhibitor/CRISPR enhancer / XL413 is a potent (IC50 = 4.8 nM) ATP-competitive inhibitor of the important DNA replication initiation kinase Cdc7 (DDK).1 It increases the efficiency of homology directed DNA repair in CRISPR-Cas9 gene editing.2 XL413 acted synergistically with other chemotherapy agents in various cancer models.3-5
Biochemicals & reagents
2062200-97-7
1) Koltun et al. (2012), Discovery of XL413, a potent and selective CDC7 inhibitor; Bioorg .Med. Chem. Lett. 22 3727 2) Wienert et al. (2020), Timed inhibition of CDC7 increases CRISPR-Cas9 mediated templated repair; Nat. Commun. 112109 3) Deng et al. (2023), Identifying CDC7 as a synergistic target of chemotherapy in resistant small-cell lung cancer via CRISPR/Cas9 screening; Cell Death Discov. 9 40 4) Zhang et al. (2023), DBF4 Dependent Kinase Inhibition Suppresses Hepatocellular Carcinoma Progression and Potentiates Anti-Programmed Cell Death-1 Therapy; Int. J. Biol. Sci. 19 3427 5) Li et al. (2024), Effective sequential combined therapy with carboplatin and a CDC7 inhibitor in ovarian cancer; Nat. Commun. 39 10185
-20°C
TARGET: Kinase -- PATHWAY: DNA synthesis -- RESEARCH AREA: CRISPR -- DISEASE AREA: Cancer